These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1. Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608 [TBL] [Abstract][Full Text] [Related]
7. 4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors. Ni ZJ; Barsanti P; Brammeier N; Diebes A; Poon DJ; Ng S; Pecchi S; Pfister K; Renhowe PA; Ramurthy S; Wagman AS; Bussiere DE; Le V; Zhou Y; Jansen JM; Ma S; Gesner TG Bioorg Med Chem Lett; 2006 Jun; 16(12):3121-4. PubMed ID: 16603354 [TBL] [Abstract][Full Text] [Related]
8. Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors. Tao ZF; Li G; Tong Y; Stewart KD; Chen Z; Bui MH; Merta P; Park C; Kovar P; Zhang H; Sham HL; Rosenberg SH; Sowin TJ; Lin NH Bioorg Med Chem Lett; 2007 Nov; 17(21):5944-51. PubMed ID: 17827013 [TBL] [Abstract][Full Text] [Related]
9. 3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6. Fraley ME; Steen JT; Brnardic EJ; Arrington KL; Spencer KL; Hanney BA; Kim Y; Hartman GD; Stirdivant SM; Drakas BA; Rickert K; Walsh ES; Hamilton K; Buser CA; Hardwick J; Tao W; Beck SC; Mao X; Lobell RB; Sepp-Lorenzino L; Yan Y; Ikuta M; Munshi SK; Kuo LC; Kreatsoulas C Bioorg Med Chem Lett; 2006 Dec; 16(23):6049-53. PubMed ID: 16978863 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors. Lin NH; Xia P; Kovar P; Park C; Chen Z; Zhang H; Rosenberg SH; Sham HL Bioorg Med Chem Lett; 2006 Jan; 16(2):421-6. PubMed ID: 16242328 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors. Liu M; Xin Z; Clampit JE; Wang S; Gum RJ; Haasch DL; Trevillyan JM; Abad-Zapatero C; Fry EH; Sham HL; Liu G Bioorg Med Chem Lett; 2006 May; 16(10):2590-4. PubMed ID: 16527482 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and preliminary structure-activity relationship study of 2-aryl-2H-pyrazolo[4,3-c]quinolin-3-ones as potential checkpoint kinase 1 (Chk1) inhibitors. Malvacio I; Cuzzolin A; Sturlese M; Vera DMA; Moyano EL; Moro S J Enzyme Inhib Med Chem; 2017 Dec; 33(1):171-183. PubMed ID: 29210298 [TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors. Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of selenophene derivatives as novel CHK1 inhibitors. Hong PC; Chen LJ; Lai TY; Yang HY; Chiang SJ; Lu YY; Tsai PK; Hsu HY; Wei WY; Liao CB Bioorg Med Chem Lett; 2010 Sep; 20(17):5065-8. PubMed ID: 20674356 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. Li G; Hasvold LA; Tao ZF; Wang GT; Gwaltney SL; Patel J; Kovar P; Credo RB; Chen Z; Zhang H; Park C; Sham HL; Sowin T; Rosenberg SH; Lin NH Bioorg Med Chem Lett; 2006 Apr; 16(8):2293-8. PubMed ID: 16446090 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors. Zhao L; Zhang Y; Dai C; Guzi T; Wiswell D; Seghezzi W; Parry D; Fischmann T; Siddiqui MA Bioorg Med Chem Lett; 2010 Dec; 20(24):7216-21. PubMed ID: 21074424 [TBL] [Abstract][Full Text] [Related]
17. Identification of inhibitors of checkpoint kinase 1 through template screening. Matthews TP; Klair S; Burns S; Boxall K; Cherry M; Fisher M; Westwood IM; Walton MI; McHardy T; Cheung KM; Van Montfort R; Williams D; Aherne GW; Garrett MD; Reader J; Collins I J Med Chem; 2009 Aug; 52(15):4810-9. PubMed ID: 19572549 [TBL] [Abstract][Full Text] [Related]
18. Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors. Huang X; Cheng CC; Fischmann TO; Duca JS; Richards M; Tadikonda PK; Reddy PA; Zhao L; Siddiqui MA; Parry D; Davis N; Seghezzi W; Wiswell D; Shipps GW Bioorg Med Chem Lett; 2013 May; 23(9):2590-4. PubMed ID: 23535330 [TBL] [Abstract][Full Text] [Related]